| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERAP2 |
| Uniprot No | Q6P179-4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-350aa |
| 氨基酸序列 | MFHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFSVPSSYHFTEDP GAFPVATNGERFPWQELRLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVL VSNATQFIILHSKDLEITNATLQSEEDSKYMKPGKELKVLSYPAHEQIAL LVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFE PTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLE DHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYAL QASLKLLDFYEKYFDIYYPLSKLGMFKFHIIVFIFAHKTCFDLFPLSLSM |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERAP2重组蛋白的3篇代表性文献的简要信息(文献标题及内容为模拟概括，供参考)：
---
1. **标题**：*Structural and functional analysis of ERAP2 reveals a role in antigen processing*
**作者**：Evnouchidou I, et al.
**摘要**：研究通过重组表达ERAP2蛋白，解析其晶体结构，揭示其底物结合域的特异性，并证明其在剪切MHC-I类分子抗原肽中的关键作用，为免疫调控提供分子机制依据。
2. **标题**：*ERAP2 synergizes with ERAP1 to modulate autoimmune disease risk*
**作者**：Saveanu L, et al.
**摘要**：通过体外重组蛋白实验，发现ERAP2与ERAP1协同作用，影响抗原肽的生成效率和长度，进而改变MHC-I分子呈递，可能与类风湿性关节炎等自身免疫疾病的遗传易感性相关。
3. **标题**：*Allelic variation in ERAP2 affects catalytic activity and HIV infection outcomes*
**作者**：Kuiper JJ, et al.
**摘要**：研究利用重组ERAP2蛋白的多种基因变异体，发现特定单核苷酸多态性(SNP)导致酶活性差异，可能通过调控抗病毒免疫应答影响HIV感染进程。
---
(注：以上文献信息为模拟生成，实际文献需通过PubMed/Google Scholar检索确认。)
ERAP2 (Endoplasmic Reticulum Aminopeptidase 2) is a member of the M1 zinc metalloprotease family, primarily involved in trimming antigenic peptides within the endoplasmic reticulum (ER) to optimize their length for loading onto major histocompatibility complex class I (MHC-I) molecules. This process is critical for adaptive immunity, as MHC-I-peptide complexes are presented on the cell surface to activate CD8+ T cells. ERAP2 works synergistically with its paralog ERAP1. exhibiting unique substrate preferences and enzymatic properties. Unlike ERAP1. ERAP2 preferentially cleaves N-terminal residues of basic or hydrophobic peptides, influencing the repertoire of antigenic peptides presented to the immune system.
Genetically, ERAP2 is highly polymorphic, with certain single-nucleotide polymorphisms (SNPs) linked to autoimmune and infectious diseases. Notably, a common splice-site variant (rs2248374) results in loss-of-function, affecting disease susceptibility. For example, ERAP2 variants are associated with ankylosing spondylitis, Crohn’s disease, and preeclampsia, highlighting its role in immune regulation and inflammation.
Recombinant ERAP2 protein is engineered to study its enzymatic activity, substrate specificity, and interactions with ERAP1 or MHC-I. Produced via heterologous expression systems (e.g., mammalian or insect cells), it retains post-translational modifications critical for function. Research applications include elucidating mechanisms of antigen processing, designing ERAP2 inhibitors for autoimmune therapies, and exploring its role in viral immune evasion (e.g., HIV, SARS-CoV-2). Additionally, recombinant ERAP2 serves as a tool to investigate how genetic variations impact enzyme kinetics and disease pathways, bridging molecular biology with clinical insights. Its study holds promise for personalized immunotherapies and vaccine development.
×
